Phase 2 trial design in neuro-oncology revisited: a report from the RANO group (Q38007230)

26 August 2017

title

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group (English)

1 reference

26 August 2017

main subject

phase II clinical trial

0 references

11

Michael Weller

1 reference

26 August 2017

8

Wolfgang Wick

1 reference

26 August 2017

7

David A Reardon

1 reference

26 August 2017

1

Evanthia Galanis

1 reference

26 August 2017

6

Patrick Y Wen

1 reference

26 August 2017

3

Timothy Cloughesy

1 reference

26 August 2017

Terri S Armstrong

10

1 reference

ORCID Public Data File 2021

Martin J van den Bent

15

object named as

Martin J van den Bent

1 reference

26 August 2017

12

Michael Vogelbaum

1 reference

26 August 2017

17

Susan Chang

1 reference

26 August 2017

Wenting Wu

2

1 reference

26 August 2017

Kathleen Lamborn

4

1 reference

26 August 2017

Bhupinder Mann

5

1 reference

26 August 2017

David Macdonald

9

1 reference

26 August 2017

Howard Colman

13

1 reference

26 August 2017

Daniel J Sargent

14

1 reference

26 August 2017

Mark Gilbert

16

1 reference

26 August 2017

publication date

1 May 2012

1 reference

Lancet Oncology Commission

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

e196-204

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Evaluating glioma therapies: modeling treatments and predicting outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Clinical trial end points for high-grade glioma: the evolving landscape.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

A three-outcome design for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Calibrated phase II clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Randomized discontinuation design: application to cytostatic antineoplastic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Evaluation of randomized discontinuation design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

A flexible design for multiple armed screening trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Integrating validity theory with use of measurement instruments in clinical settings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970406-5

7 January 2021

10.1016/S1470-2045(11)70406-5

Identifiers

DOI

1 reference

release_lvayehajb5fzdikqhgqbz5b5ey

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lvayehajb5fzdikqhgqbz5b5ey

24 November 2022

mapped directly with Wikidata item

1 reference